提升COVID-19感染后持续肺部异常患者的临床诊断:68Ga-FAPI PET/CT的潜在获益
6例COVID-19后疑似肺纤维化患者接受18F-FDG与68Ga-FAPI-46双示踪剂PET/CT,并与9例非COVID-19对照比较。所有6例肺部受累患者在18F-FDG上葡萄糖亲和力降低,而68Ga-FAPI-46 PET/CT呈明显阳性。作者认为68Ga-FAPI PET/CT可能改善重症COVID-19后长期CT异常患者的无创临床诊断效能,但需更大样本研究以建立通用诊断指南。
要点
- 6例COVID-19后疑似肺纤维化患者中,18F-FDG摄取减低而68Ga-FAPI-46呈明显阳性。
- 与9例非COVID-19对照相比,68Ga-FAPI-46在受累肺组织中的摄取呈明显阳性。
- 作者认为68Ga-FAPI PET/CT可能改善重症COVID-19后长期CT异常患者的无创诊断效能。
核心结论
- 68Ga-FAPI PET/CT通过增强纤维化修复机制的可视化,可能改善重症COVID-19后长期CT异常患者的无创临床诊断效能。
- 尽管结果有前景,仍需更大规模人群的额外研究以建立通用诊断指南。
研究设计与样本
- 6例COVID-19后疑似肺纤维化患者接受18F-FDG与68Ga-FAPI-46双示踪剂PET/CT检查。
- 设立9例非COVID-19患者作为对照组,比较受累肺组织中68Ga-FAPI-46的摄取。
- 收集并分析临床数据与PET/CT影像。
主要发现
- 全部6例肺部受累患者在18F-FDG PET/CT上显示葡萄糖亲和力降低。
- 全部6例肺部受累患者在68Ga-FAPI-46 PET/CT上显示明显阳性,与对照组相比。
- 18F-FDG摄取减低与68Ga-FAPI-46明显阳性在全部6例中同时出现。
临床怎么用
- 作者认为68Ga-FAPI PET/CT可能改善重症COVID-19后长期CT异常患者的无创临床诊断效能。
- 作者指出仍需更大规模人群的额外研究以建立通用诊断指南。
局限性
- 本研究样本量小,仅纳入6例COVID-19后患者和9例对照。
- 作者指出仍需更大规模人群的额外研究以建立通用诊断指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PATIENTS AND METHODS: Six post COVID-19 patients suspected for pulmonary fibrosis were scheduled for dual-tracer PET/CT with 18 F-FDG and 68 Ga-fibroblast activation protein inhibitor (FAPI)-46. The uptake of 68 Ga-FAPI-46 in the involved lung was compared with a control group of 9 non-COVID-19 patients. Clinical data and PET/CT imaging were collected and analyzed. RESULTS: PET/CT revealed in all 6 pulmonary impaired patients the reduced glucose avidity on 18 F-FDG and clear positivity on 68 Ga-FAPI-46 PET/CT in comparison to the control group. CONCLUSIONS: Enhancing fibrotic repair mechanisms, 68 Ga-FAPI PET/CT may improve noninvasive clinical diagnostic performance in patients with long-term CT abnormalities after severe COVID-19. Although this study shows promising results, additional studies in larger populations are required to establish a general diagnostic guideline.
引用
- Sviridenko A, Boehm A, di Santo G, et al. Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68 Ga-FAPI PET/CT. Clin Nucl Med. 2022. PMID: 36257062. doi:10.1097/RLU.0000000000004437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。